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introduction: Liver cancer is the fastest increasing cancer in the United States and is 
one of the leading causes of cancer-related death in New York City (NYC), with wide 
disparities among neighborhoods. The purpose of this cross-sectional study was to 
describe liver cancer incidence by neighborhood and examine its association with risk 
factors. This information can inform preventive and treatment interventions.
Materials and methods: Publicly available data were collected on adult NYC residents 
(n =  6,407,022). Age-adjusted data on liver and intrahepatic bile duct cancer came 
from the New York State Cancer Registry (1) (2007–2011 average annual incidence); 
and the NYC Vital Statistics Bureau (2015, mortality). Data on liver cancer risk factors 
(2012–2015) were sourced from the New York City Department of Health and Mental 
Hygiene: (1) Community Health Survey, (2) A1C registry, and (3) NYC Health Department 
Hepatitis surveillance data. They included prevalence of obesity, diabetes, diabetic 
control, alcohol-related hospitalizations or emergency department visits, hepatitis B and 
C rates, hepatitis B vaccine coverage, and injecting drug use.
results: Liver cancer incidence in NYC was strongly associated with neighborhood 
poverty after adjusting for race/ethnicity (β = 0.0217, p = 0.013); and with infection risk 
scores (β = 0.0389, 95% CI = 0.0088–0.069, p = 0.011), particularly in the poorest neigh-
borhoods (β = 0.1207, 95% CI = 0.0147–0.2267, p = 0.026). Some neighborhoods with 
high hepatitis rates do not have a proportionate number of hepatitis prevention services.
conclusion: High liver cancer incidence is strongly associated with infection risk factors 
in NYC. There are gaps in hepatitis prevention services like syringe exchange and vacci-
nation that should be addressed. The role of alcohol and metabolic risk factors on liver 
cancer in NYC warrants further study.
Keywords: hepatocellular carcinoma, chronic hepatitis, health-care disparities, low-income populations, 
vaccinations, cancer screening
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inTrODUcTiOn
Cancer of the liver and intrahepatic bile ducts (liver cancer) is a 
public health problem in the United States (US). Since 1980, its 
nationwide incidence rate has tripled, and its mortality rate has 
doubled, outpacing the increase in any other cancer (2). Only 31% 
of those with localized liver cancer survive 5 years past diagnosis. 
The 5-year survival rate for regional and distant liver cancer is 
even poorer at 11 and 3%, respectively (2). Several studies have 
succeeded in reducing liver cancer incidence, most effectively 
through hepatitis B vaccination, and to an extent through antiviral 
therapy for hepatitis B and C (3). Although liver cancer prognosis 
can be improved by early detection and treatment during its long 
subclinical course, this is a challenge since liver cancer is usually 
asymptomatic in its early stages (3, 4). Currently, no guidelines 
currently exist for routine liver cancer screening in people of 
average risk; however, people at higher risk due to cirrhosis and/
or chronic hepatitis B infection may benefit from screening with 
ultrasound exams, with or without alpha-fetoprotein blood tests, 
twice a year (5).
In New York City (NYC), liver cancer is the fifth leading cause 
of cancer-related death among men and seventh among women 
(1). The 2010–2014 age-adjusted liver cancer incidence rate in 
NYC was 12 per 100,000 residents, higher than the US (7.8) and 
New York State (NYS) (8.6) (1, 6). The age-adjusted mortality 
rate per 100,000 was also higher at 7.7 compared with the US 
(6.3) and NYS (6.1) (1, 6). Certain neighborhoods have incidence 
rates of 16–22.2 per 100,000, comparable to Asia, West Africa, 
and Central/South America (7).
New York City is a microcosm of the global population due 
to its unique demographics, high percentage of foreign-born 
inhabitants, and diversity of country of origin. Although a recent 
review examined racial/ethnic liver cancer disparities in the US 
(8), it has not been studied on a local level. A study of cancer 
incidence in NYC and three of its neighborhoods (East Harlem, 
Central Harlem, and Upper East Side) found that neighborhood 
was associated with incidence of all cancers, including liver 
cancer (9). To understand the basis for NYC disparities in liver 
cancer incidence and mortality, it is crucial to identify high-risk 
subpopulations, the risk factors most strongly associated with 
liver cancer, and how they are distributed in the city. The informa-
tion can help inform preventive and treatment interventions for 
communities that require them the most.
MaTerials anD MeThODs
Data collection
Data were collected from the pool of adult (≥18  years) NYC 
residents (n  =  6,407,022 per the 2010 US Census) at the 
neighborhood level, and defined neighborhood borders using 
NYC United Hospital Fund (UHF) codes. Originally, the UHF 
divided NYC into 42 distinct neighborhoods by combining 
adjoining zip codes areas with similar characteristics, meant to 
approximate NYC Community Planning Districts. To increase 
statistical power, these were later collapsed into 34 neighbor-
hoods (10).
Primary Outcomes
Cancer data for NYC included age-adjusted incidence and mor-
tality rates per 100,000 residents from the NYS Cancer Registry 
(1). The average incidence rate was calculated from the number of 
residents diagnosed with liver and/or intrahepatic bile duct can-
cer over 2007–2011, divided by the corresponding age-specific 
intercensal population estimates (from the NYS Department of 
Health). Age adjustment was based on the US Census 2000 stand-
ard population. Mortality rate estimates for 2015 were obtained 
from the NYC Department of Health and Mental Hygiene 
(NYCDOHMH) using the online interactive tool, Epiquery (11). 
Crude mortality rates are presented for neighborhoods with small 
numbers and/or unreliable age-adjusted estimates. For all out-
comes, the most recent available estimates at the neighborhood 
level are presented.
Sociodemographics
Data on gender and race/ethnicity were collected from the 
2010 US Census, and neighborhood-specific distributions were 
extracted using Epiquery. Data on poverty were obtained from 
the American Community Survey conducted by the US Census 
Bureau (12). Poverty was defined as the % of people reporting 
annual incomes below the federal poverty threshold during 
2010–2014 ($11,139–$12,071 for one person). Data on insurance 
coverage were obtained from the Community Health Survey 
(CHS), an annual telephone survey conducted among NYC 
residents ≥18 years by the NYCDOHMH (13). We report the % 
of people who had no type of health insurance coverage.
Risk Factors for Liver Cancer
Viral hepatitis data are derived from surveillance reports filed by 
the Bureau of Communicable Disease (14). They include con-
firmed or probable cases of chronic hepatitis B and C reported to 
the Health Department by health-care providers and laboratories 
meeting the definitions by the Centers for Disease Control/
Council of State and Territorial Epidemiologists’ (positive 
hepatitis B surface antigen, hepatitis B e-antigen, and hepatitis B 
nucleic acid test; enzyme-linked immunosorbent assay antibody 
test with a high signal-to-cutoff value; recombinant immunoblot 
assay; and RNA test for hepatitis C).
Prevalence of self-reported current smoking (proportion of 
people who reported smoking cigarettes daily or on some days 
as of the interview day), injecting drug use (% of people who 
reported having used a needle to inject non-prescription drugs 
at least once), obesity (body mass index ≥30 kg/m2), diabetes (% 
of people who reported ever being told by a health-care profes-
sional that they have diabetes), and physical activity (% of adults 
who reported in the past 30 days: (1) exercising (running, calis-
thenics, golf, gardening, or walking, other than at their regular 
job) and (2) walking/bicycling >10 blocks for transportation) 
were obtained via the CHS (13). Diabetes control was measured 
by data from the NYC A1C Registry. We report the % of diabetic 
adults (history of ≥2 glycosylated hemoglobin, or A1C, test 
values ≥  6.5%) who received medical care in 2012, with their 
last A1C measurement ≥9% (15).
As a proxy for alcohol use, clinical data on the number of 
patients who were hospitalized or visited an emergency department 
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(ED) during 2014 were abstracted from the mandatory NYS 
hospital discharge abstract database (16), using the ICD-9 codes 
291.0–291.5, 291.8, 291.9, 303.00–303.93, 305.00–305.03, 357.5, 
425.5, 535.3, 571.1–4, 571.5, 571.9, 572.3, 577.1 (diagnoses of 
alcohol-related morbidity) (17), and of alcohol poisoning (790.3, 
980, E860) (18). Only one hospitalization/ED visit per patient 
was counted. Approval to collect data under exempt status was 
obtained from Mount Sinai’s Institutional Review Board.
Preventive Services
Data on the availability of preventive services providing hepatitis 
B or C testing and treatment, hepatitis B vaccination, and syringe 
exchange facilities were collected from the NYC Health Map 
website (19), which lists names and addresses of clinics by service 
type. The number of services in each UHF neighborhood was 
obtained by matching address zip codes. The % of NYC residents 
who reported ever having received at least 1 dose of the hepatitis 
B vaccine and ever getting tested for hepatitis C was obtained 
from the CHS.
statistical analyses
Descriptive data are presented for the entire city, and each neigh-
borhood in the form of tables and density maps prepared using 
ArcGIS Desktop (version 10.3.1; ESRI, Redlands, CA). Predictors 
were weighted risk scores calculated for three domains of modi-
fiable liver cancer risk factors: (1) metabolic (obesity, diabetes, 
and proportion of A1C  ≥  9%); (2) alcohol-related morbidity 
(hospitalizations, ED visits); and (3) infections (rates of newly 
reported hepatitis B and C cases, hepatitis B vaccination coverage, 
and self-reported injecting drug use). Each continuous item was 
given an ordinal score based on tertiles, quartiles, or a specific 
cutoff. For each item, neighborhoods received a prevalence score 
from 1 to 3 based on increasing tertiles (quartiles 1–4 for hepatitis 
B). Hepatitis B vaccine coverage was reverse scored to reflect a 
protective effect. Due to the distribution, a cutoff of <1% and 
≥1% was used to score injecting drug use prevalence category as 
1 or 2. Each item was also assigned a correlation score from 1 to 3 
based on the strength of its correlation with liver cancer incidence 
(Pearson’s r ≤ 0.3, 0.3 < r < 0.5, r ≥ 5). Prevalence scores were 
multiplied by the correlation scores to obtain item scores, which 
were summed up to produce a risk score for each domain.
Spatial autocorrelation of liver cancer incidence was assessed 
using Moran’s global index (Moran’s I statistic) (20). A sensitivity 
analysis was conducted to evaluate the effect of spatial depend-
ence by comparing linear regression models with and without a 
spatial lag term. The spatial lag model was run by adding a spatial 
weights matrix as an independent variable with weights based on 
inverse distances between neighborhood centroid coordinates. 
All spatial analyses were conducted using the spatial software 
GeoDa version 1.12.1.129.
The relationship between liver cancer incidence and each 
predictor was assessed in unadjusted and adjusted generalized 
linear regression models, with neighborhood as the unit of analy-
sis (n = 34) (SAS Proprietary Software 9.4, TS1M1). All models 
met the assumptions for the specified Poisson distribution (21). 
Stratified analyses by prevalence of neighborhood poverty were 
conducted. Point estimates, 95% Wald confidence intervals, and 
p-values for the regression coefficient β were evaluated at a sta-
tistical significance level of α = 0.05 (two-sided hypothesis test).
resUlTs
New York City’s racial and ethnic composition includes 33% 
non-Hispanic White, 29% Hispanic, 23% African-American, 
13% Asian or Pacific Islander, and 3% other races. Half of NYC 
residents (53%) are female, 21% live in poverty, and 13% are 
uninsured. There was considerable variation in the distribution 
of demographic characteristics according to neighborhood 
(Table 1).
liver cancer statistics
During 2007–2011, there was an average of 921.4 cases of liver and 
intrahepatic bile duct cancer in NYC annually. The age-adjusted 
incidence rates were highest in the Bronx [South Bronx (22.3), 
Fordham/Bronx Park (15), and Pelham/Throgs Neck (13.7)]; 
Manhattan [Union Square and Lower Manhattan (15.9), Central 
Harlem (15.8), East Harlem (15.7), and Washington Heights/
Inwood (13.3)], and Brooklyn [Sunset Park (16.7)] (Figure  1). 
Mortality rates follow similar geographic distribution, with the 
highest mortality rates in Sunset Park (12.6), Fordham/Bronx Park 
(12.1), South Bronx (11.6), Union Square and Lower Manhattan 
(11.5), Pelham/Throgs Neck (11), and Central Harlem (9.2). Two 
neighborhoods showed high mortality rates despite relatively 
lower incidence: Williamsburg/Bushwick in Brooklyn (10.6) and 
Ridgewood/Forest Hills in Queens (9.1).
liver cancer risk Factors
The distribution of individual liver cancer risk factors is presented 
in Table 2. Obesity was less prevalent in NYC (24%) compared 
with the US average (≈38%) (4) but varied widely from 8% in 
the Upper West Side to 37% in East New York. East Harlem had 
the highest prevalence of self-reported diabetes (23%) and poor 
glycemic control (21%). A high proportion of poorly controlled 
diabetes was also observed in East New York, Bedford–Stuyvesant/
Crown Heights, Williamsburg/Bushwick, the South Bronx, and 
Fordham/Bronx Park. There was relatively less variation in self-
reported physical activity. East Harlem had the highest preva-
lence of self-reported injecting drug use at 4.7%, followed by 
Upper West Side (2.1%), and the South Bronx (1.8%). Cigarette 
smoking was most prevalent in Greenpoint (21%), Long Island 
City/Astoria, and Ridgewood/Forest Hills (19%). Finally, the 
mean and range of composite scores for the three modifiable risk 
factor domains (metabolic, alcohol, and infection) are presented 
in Table 3. Alcohol risk scores were moderately correlated with 
metabolic and infection risk scores; however, results of statistical 
tolerance tests did not indicate a significant threat of multicol-
linearity on the model estimates (22).
association Between Distribution of liver 
cancer incidence and risk Factor scores
Neighborhood-level data on poverty and Hispanic ethnicity 
were associated with high liver cancer incidence (β =  0.0277, 
p < 0.0001, and β = 0.0113, p < 0.0001), even after adjustment 
TaBle 1 | Distribution of sociodemographic characteristics according to neighborhood.
neighborhood % Malea race/ethnicity (% of population)a % living in povertyb % Uninsuredc
White Black hispanic asian/Pacific islander Other
Kingsbridge/Riverdale 45.0 42.5 11.1 39.8 4.7 1.9 16.1 2.7
The Northeast Bronx 44.7 11.1 58.8 24.4 2.8 2.9 15.4 10.3
Fordham/Bronx Park 47.4 8.7 24.8 59.6 5.0 2.0 32.9 18
Pelham/Throgs Neck 47.0 20.4 20.7 49.7 6.6 2.7 23.2 11.8
South Bronxd 46.9 1.5 29.5 66.5 1.0 1.4 41.2 11.9
Greenpoint 49.5 68.1 2.9 23.0 4.1 1.9 26.5 8.6
Downtown Brooklyn/Heights/Slope 47.1 56.6 15.5 18.1 6.5 3.3 16.4 10.3
Bedford–Stuyvesant/Crown Heights 44.8 11.2 71.4 13.1 1.9 2.5 27.2 11.4
East New York/New Lots 46.1 1.9 51.2 38.8 4.7 3.4 33.4 3.8
Sunset Park 51.4 15.8 2.3 44.6 35.7 1.6 31.1 27.4
Borough Park 49.4 61.0 4.3 12.8 20.0 1.8 26.9 16.0
Flatbush 45.0 11.9 72.4 10.9 2.3 2.4 18.6 14.3
Canarsie and Flatlands 44.4 24.1 61.4 8.9 3.5 2.1 13.3 8.5
Bay Ridge/Bensonhurst 48.5 60.3 1.1 13.4 23.4 1.8 16.0 13.2
Coney Island 47.2 64.7 6.6 11.7 15.4 1.6 20.4 11.3
Williamsburg/Bushwick 48.5 14.6 30.4 48.7 4.5 1.8 31.5 10.4
Washington Heights/Inwood 48.0 15.9 12.0 68.0 2.5 1.7 25.4 18.7
Central Harlem 45.6 13.9 54.6 24.2 4.3 2.9 29.8 5.3
East Harlem 47.1 11.7 29.0 51.7 5.6 2.0 32.9 14.7
Upper West Side 45.8 67.2 7.5 14.9 7.9 2.5 11.6 7.8
Upper East Side–Gramercyd 45.0 75.5 3.4 7.4 11.5 2.2 8.4 7.8
Chelsea Villaged 50.4 66.0 4.0 10.6 16.6 2.8 11.0 12.2
Union Sq–Lower Manhattand 48.1 45.7 6.8 10.0 50.4 8.0 16.1 5.2
Long Island City/Astoria 49.4 46.9 6.1 27.1 16.6 3.3 16.7 9.6
West Queens 51.9 16.1 5.9 51.4 24.5 2.1 19.2 29.0
Flushing/Clearview 47.7 31.3 2.1 16.2 48.4 1.9 15.2 12.8
Bayside-Fresh Meadowsd 47.5 44.0 5.2 12.2 36.2 2.3 11.6 7.5
Ridgewood/Forest Hills 47.7 54.5 2.0 26.1 15.5 2.0 13.1 17.6
Southwest Queens 49.0 22.6 12.4 32.7 20.2 12.1 14.3 9.5
Jamaica 46.7 7.1 53.9 18.0 14.5 6.5 16.0 19.6
Southeast Queens 46.4 13.6 54.9 11.8 14.7 5.1 7.6 9.5
The Rockaways 47.0 35.2 38.8 21.0 2.3 2.7 20.2 8.4
Northern Staten Islandd 48.5 40.2 21.0 28.9 7.5 2.4 20.4 10.1
Southern Staten Islandd 48.4 76.0 2.5 11.1 8.8 1.5 7.7 4.1
NYC 47.5 33.3 22.8 28.6 12.6 2.7 20.6 12.6
aUnited States Census, 2010.
bAmerican Community Survey, percentage with annual income below 100% of federal poverty threshold, 2010–2014.
cNew York City (NYC) Department of Health and Mental Hygiene. Epiquery: NYC Interactive Health Data System—[Community Health Survey 2015] [08/28/2017].  
http://nyc.gov/health/epiquery.
dGender, race, and poverty data for combined neighborhoods are averages of constituent UHF 42 neighborhoods.
All percentages are age-adjusted using the 2010 US Census standard population.
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for White race and Hispanic ethnicity (β = 0.0217, p = 0.013). A 
higher proportion of foreign-born residents was correlated with 
higher rates of hepatitis B (r = 0.48, p = 0.0037).
Among the three modifiable risk factor domains, infection 
was the strongest predictor of liver cancer incidence, with an 
expected increase of 5.3% in incidence when the infection risk 
score increased by 1 (p <  0.0001), followed by alcohol-related 
morbidity (4.8% increase, p =  0.001) (Table 3). Metabolic risk 
score was also weakly but positively associated with liver cancer 
incidence (3% increase, p = 0.052). We conducted formal test-
ing by including interaction terms between poverty tertiles and 
each of the three risk scores (metabolic, alcohol, and infection), 
and observed lack of statistical interaction. When stratified by 
tertiles of poverty prevalence, infection score was most strongly 
associated with liver cancer incidence at the high poverty level 
(10% increase, p = 0.027). Similarly, infection risk score was most 
strongly associated with liver cancer incidence (4% increase, 
p = 0.011), especially at the high poverty level (12.8% increase, 
p =  0.026), in models that adjusted for metabolic and alcohol 
risk score.
spatial autocorrelation sensitivity analysis
The Moran’s I test indicated the presence of a significant positive 
spatial autocorrelation for the outcome, liver cancer incidence 
(I = 0.28, p = 0.005). Comparison of ordinary least squares regres-
sion and a spatial lag model found no meaningful effect of spatial 
autocorrelation on model estimates (Table S1 in Supplementary 
Material).
Preventive services
The number of centers offering preventive services are 80, 89, 
and 28, respectively, for hepatitis B testing, treatment, and vaccina-
tion; 127 and 128, respectively, for hepatitis C testing and treatment; 
23 syringe exchange programs (SEPs), with multiple additional 
FigUre 1 | Liver cancer incidence and mortality rates according to neighborhood.
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distribution locations, and hundreds of Expanded Syringe Access 
Program locations throughout NYC. Their availability in relation 
to hepatitis burden is depicted in Figures 2 and 3.
DiscUssiOn
To the best of our knowledge, this is the first study to describe 
liver cancer incidence and the distribution of its underlying risk 
factors at a neighborhood level in NYC. In addition, this is the 
first study to assess the availability of hepatitis prevention and 
treatment services in the context of disease burden.
Results indicate that not only does NYC have higher rates of 
liver cancer incidence and mortality compared with NY State 
and the rest of the US but also large disparities exist among city 
neighborhoods, with incidence rates in some neighborhoods as 
high as those in China and West Africa (7). The most striking 
finding was the strong relationship between poverty, liver cancer, 
and its risk factors, even after adjusting for other demograph-
ics and risk factor scores. Of the three modifiable risk factor 
domains, infection was most strongly and consistently associ-
ated with liver cancer incidence. Rates of newly reported chronic 
hepatitis B and C in NYC show a gradual rise since 2013 (9, 10). 
This could be partially attributed to improved surveillance and 
test sensitivity and updated US Department of Health guidelines 
for Hepatitis C testing in “baby boomers” (23). However, recent 
changes in drug use patterns could explain the rise in both hepa-
titis B and C rates. The National Institute of Drug Abuse reported 
that the % of drug reports identified as heroin, a common inject-
able drug, increased from 10.4% in 2012 to 11.6% in 2013 in 
NYC, along with a decrease in the average age at admission to 
substance abuse treatment (24).
Recent immigration patterns may also contribute toward 
the observed increase in hepatitis B. Between 2000 and 2011, 
NYC has seen a 4% increase in foreign-born residents (25). 
Neighborhoods with the highest gains (≥5,000 people) include 
East and Central Harlem, Lower Manhattan, parts of the South 
Bronx, Sunset Park, etc. (25). The same neighborhoods have seen 
high immigration from three countries with high prevalence 
of hepatitis B (China: 5.49%, Dominican Republic: 4.09%, and 
TaBle 2 | Distribution of behavioral liver cancer risk factors according to neighborhood.











Kingsbridge/Riverdale 8.3 0 83.4 73.9 33.3 8.7 15.1 51.7 28.3
The Northeast Bronx 12.3 0 72.4 78.7 28.2 10.1 17.5 58.0 54.1
Fordham/Bronx Park 10.4 1.39 71.2 80.0 28.6 18.4 20.2 47.8 46.3 LC, M, I, P
Pelham/Throgs Neck 16.5 0.79 73.2 76.3 29.9 11.9 19.2 51.1 42.8 LC
South Bronxe 17.0 1.76 70.4 82.1 34.4 20.2 20.7 47.1 52.4 LC, M, A, I, P
Greenpoint 20.7 0 77.9 85.1 26.2 9.4 16.2 37.8 41.0
Downtown Brooklyn/Heights/
Slope
13.5 0.64 81.2 92.0 16.1 4.6 17.1 60.7 36.1
Bedford–Stuyvesant/Crown 
Heights
17.9 0.23 72.8 78.1 36.3 13.6 21.1 53.7 57.2 A, P
East New York/New Lots 12.3 0.19 72.3 73.5 37.1 21.7 21.5 50.1 46.5 M, A, P
Sunset Park 15.3 1.51 67.1 93.1 23.6 12.1 15.6 32.9 33.4 LC, I, P
Borough Park 15.1 0.48 69.8 77.8 16.3 8.8 13.4 45.3 26.7 I
Flatbush 9.4 1.03 72.9 82.0 35.6 13.7 19.6 51.1 47.3
Canarsie and Flatlands 8.0 0 76.4 75.1 29.1 13.9 18.2 45.0 43.8
Bay Ridge/Bensonhurst 15.2 0.85 73.0 83.5 21.2 10.3 12.4 33.5 30.9 I
Coney Island 18.4 0.93 68.4 82.6 26.8 13.7 12.5 39.9 36.2 I
Williamsburg/Bushwick 18.0 1.52 69.7 79.9 25.9 15.0 21.2 42.6 46.7 M, A, I, P
Washington Heights/Inwood 12.0 0.44 76.8 81.2 25.8 14.1 18.6 38.0 41.9 LC, M
Central Harlem 12.8 0.21 74.2 81.1 31.4 13.7 19.6 40.7 45.9 LC, I, P
East Harlem 16.8 4.66 65.9 83.6 27 23.1 20.7 57.3 58.3 LC, M, A, I, P
Upper West Side 13.0 2.07 91.1 90.8 7.8 6.9 14.2 63.4 37.4
Upper East Side-Gramercye 10.2 0.4 87.6 92.1 12.5 4.1 11.3 47.6 37.4
Chelsea Villagee 13.2 0.6 84.2 91.3 9.3 4.8 13.1 60.6 52.1 I
Union Sq–Lower Manhattane 17.0 0.19 79.8 88.4 7.9 9.3 13.3 49.9 43.9 LC, A, I
Long Island City/Astoria 19.1 0.51 80.2 85.5 25.1 9.8 15.4 42.7 29.4
West Queens 17.8 0.27 73.6 89.4 21.1 9.6 16.0 35.5 30.3 I
Flushing/Clearview 11.5 0.25 67.7 79.2 17.2 10.7 11.3 45.1 43.3
Bayside-Fresh Meadowse 9.1 0.17 75.1 78.4 19.1 14.2 10.4 53.3 30.9
Ridgewood/Forest Hills 18.8 0 70.5 83.8 17.5 5.1 13.0 40.9 36.7
Southwest Queens 12.8 1.38 67.3 72.6 28.6 20.4 17.6 42.8 37.6
Jamaica 6.7 0.05 67.1 79.8 30.8 13.6 17.3 40.2 44.5
Southeast Queens 11.0 0 74.2 69.1 26.0 12.2 16.7 54.0 45.5
The Rockaways 16.0 0.85 69.5 77.3 34.1 13.9 18.4 41.0 53.4 M, A
Northern Staten Islande 17.5 0 78.5 74.2 23.7 9.0 17.9 45.2 41.1
Southern Staten Islande 17.5 0.37 79.3 65.5 24.6 6.2 12.4 47.9 33.1
NYC 14.3 0.66 74.5 81.6 24.1 11.6 17.0 46.6 41.4
LC, liver and bile duct cancer incidence rate; M, metabolic risk factor score; A, alcohol risk factor score; I, infection risk factor score; P, poverty.
aNew York City (NYC) Department of Health and Mental Hygiene. Epiquery: NYC Interactive Health Data System—[Community Health Survey (CHS) 2015] [08/29/2017].  
http://nyc.gov/health/epiquery.
bInjecting drug use: NYC Department of Health and Mental Hygiene. CHS [2012]; public use dataset accessed on 09/08/2017.
cNYC A1C Registry, 2012; rates based on registrants reported with likely diabetes (based on a history of ≥2 A1C test values ≥ 6.5%).
dNYC residents ages ≥18 years; rates are per 100,000 adults and are age-adjusted to 2000 Census (July 2013 NYSDH population estimates).
eA1C registry data for combined neighborhoods are averages of constituent UHF 42 neighborhoods.
fNYC Department of Health and Mental Hygiene. Epiquery: NYC Interactive Health Data System—[CHS 2012] [09/08/2017]. http://nyc.gov/health/epiquery.
gNYC Department of Health and Mental Hygiene. Epiquery: NYC Interactive Health Data System—[CHS 2013] [09/08/2017]. http://nyc.gov/health/epiquery.
hAll percentages are age-adjusted using the 2010 US Census standard population.
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Jamaica: 3.76%) (26), mirroring their own high hepatitis B rates. 
Chinese-born immigrants in NYC were found to have high 
seroprevalence of hepatitis B and increased risk for liver cancer 
(27). Another study found hepatitis B prevalence of 9.6% among 
a sample of African-born participants residing mostly in Central 
Harlem and the South Bronx (28). Immigrant health is an impor-
tant public health issue in a diverse city like NYC. Most liver 
cancer risk factors are preventable, but due to poverty or other 
issues, health policies may not have the desired effect. Ongoing 
surveillance for hepatitis and effective and timely culturally and 
linguistically competent prevention and treatment may be the 
key to preventing progression to liver cirrhosis and liver cancer 
in NYC residents. The population of certain areas in Harlem and 
Bronx is ideal for exploring preventive public health strategies, 
and implementing surveillance programs.
Preventive and treatment services for hepatitis are available 
throughout the city, but not all neighborhoods with high hepa-
titis rates have a proportionate number of required services. We 
observed that high hepatitis B rates were correlated with lower 
vaccine coverage and lower proportion of free vaccination 
TaBle 3 | Association between liver cancer incidence and risk factor scores.
risk factor domain scores, mean 
(range)
Unadjusted model adjusted modela
β 95% ci % changeb p β 95% ci % changeb p
Overall population
Metabolic score 9.8 (5–15) 0.0292 −0.0002 to 0.0587 3.0 0.052 0.0001 −0.0345 to 0.0348 0.0 0.995
Alcohol score 9.9 (5–15) 0.0465 0.0195 to 0.0735 4.8 0.001 0.025 −0.0112 to 0.0613 2.5 0.176
Infection score 15.3 (8–24) 0.0513 0.0256 to 0.077 5.3 <0.0001 0.0389 0.0088 to 0.069 4.0 0.011
By poverty level
high poverty
Metabolic score 12.4 (5–15) 0.0211 −0.0371 to 0.0792 2.1 0.478 −0.0862 −0.2697 to 0.0973 −8.3 0.357
Alcohol score 13.1 (5–15) 0.0186 −0.041 to 0.0782 1.9 0.541 0.0816 −0.0949 to 0.2582 8.5 0.365
Infection score 19.2 (16–28) 0.095 0.0109 to 0.179 10.0 0.027 0.1207 0.0147 to 0.2267 12.8 0.026
Medium poverty
Metabolic score 9.5 (5–15) −0.0131 −0.0675 to 0.0413 −1.3 0.637 −0.0235 −0.079 to 0.032 −2.3 0.407
Alcohol score 10.0 (5–15) 0.0272 −0.0224 to 0.0768 2.8 0.283 0.0332 −0.019 to 0.0854 3.4 0.213
Infection score 14.9 (8–22) 0.008 −0.0332 to 0.0492 0.8 0.705 0.0018 −0.0401 to 0.0437 0.2 0.932
low poverty
Metabolic score 8.0 (5–13) −0.015 −0.084 to 0.0539 −1.5 0.700 −0.0075 −0.0785 to 0.0635 −0.7 0.836
Alcohol score 7.0 (5–12) 0.0106 −0.0611 to 0.0823 1.1 0.773 −0.0181 −0.1002 to 0.064 −1.8 0.666
Infection score 12.6 (8–18) 0.0504 −0.022 to 0.1228 5.2 0.172 0.0578 −0.0263 to 0.1419 6.0 0.178
aAll adjusted models include the following variables: metabolic score, alcohol score, and infection score.
bPercentage change in incidence of liver cancer per unit increase in risk score: calculated as (eβ − 1) × 100.
FigUre 2 | Prevalence of hepatitis B and availability of preventive services.
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centers. Lower insurance coverage was also strongly correlated 
with lower vaccine coverage. Hepatitis B vaccination can cost 
$120–$370 without insurance, plus consultation/professional 
administration fees. This is largely unaffordable for less afflu-
ent, uninsured people. Non-monetary factors such as having a 
vaccinated acquaintance, perceived risk of disease, perceived 
vaccine safety, and provider recommendation may also influ-
ence patients’ choice to receive the hepatitis B vaccine (29). 
Therefore, a multi-pronged intervention is required to increase 
hepatitis B vaccine coverage in NYC, addressing disease-spe-
cific knowledge, access, affordability, and psychosocial factors.
While hepatitis C-related services were found to be more 
numerous, some neighborhoods appear to have fewer than 1 SEP 
per 1,000 hepatitis cases (Fordham–Bronx Park and Bedford–
Stuyvesant–Crown Heights), while others (Coney Island and 
West Queens) have fewer than one hepatitis C testing and treat-
ment centers per 100 hepatitis C cases. Although residents in 
poorer neighborhoods were more likely to get tested for hepatitis 
C, there is no information on how many of those who tested 
positive cleared the virus or received treatment. Without insur-
ance, hepatitis C drugs for a 12-week course can cost between 
$39,600 and $94,500 (30, 31). Even with insurance, arranging 
for prior authorization of hepatitis C treatment is often time 
consuming and a barrier to patients starting treatment, e.g., most 
NYS insurance providers require a prescription to be written by 
or in consultation with a specialist (32). Hepatitis C treatment 
for those who cannot obtain health insurance is provided by 
the NYS Hepatitis C Patient Assistance Program HepCAP (33). 
However, many of them are not eligible for HepCAP, highlighting 
important gaps in current hepatitis C management.
This study has some limitations: as an ecological study based 
on the most recently available data, the neighborhood-level 
associations may not reflect individual risk of liver cancer; thus 
the results should be interpreted in a geographical context only. 
Surveillance data for hepatitis B and C may include people that 
no longer have active infection, and therefore these should not be 
considered incidence or prevalence rates, but simply the number 
of newly reported cases. Hepatitis may also be underdiagnosed 
due to the passive nature of surveillance data, since active test-
ing is more costly and resource intense. Study power to detect 
significant associations could be restricted by small sample size 
(n = 34). Age, sex, and racial/ethnic diversity are other potential 
FigUre 3 | Prevalence of hepatitis C and availability of preventive services.
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